These preliminary results hinted that gardenoside is a potential anti-NAFLD drug and its mechanism of action may involve inflammasome and pyroptosis regulated by the CTCF/DPP4 axis, which was aimed to be clarified in the subsequent experiments, where 50 μM gardenoside was used. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.